--- title: "Solésence Reports Second Quarter 2026 Financial Results | SLSN Stock News" type: "News" locale: "en" url: "https://longbridge.com/en/news/296401477.md" description: "Solésence, Inc. (Nasdaq: SLSN) reported Q2 2026 financial results, showing revenue of $15.3 million and a net loss of $158,000, compared to $20.4 million revenue and $3.2 million net income in the prior year period. The company filed its Form 10-Q with the SEC and announced a conference call for August 19, 2026, to discuss results." datetime: "2026-08-19T13:05:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296401477.md) - [en](https://longbridge.com/en/news/296401477.md) - [zh-HK](https://longbridge.com/zh-HK/news/296401477.md) generator: "portal-rs" --- # Solésence Reports Second Quarter 2026 Financial Results | SLSN Stock News See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google Add on Google *Quarterly Report Filed on Form 10-Q* *Company to Host Conference Call at 5:00 p.m. ET Today* ROMEOVILLE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically driven health care solutions across beauty and life science categories, today reported its financial results for the second quarter ended June 30, 2026. “In the second quarter, our business focused on operational execution and financial discipline as we continue implementing our Transform and Transcend strategy,” said Kevin Cureton, President and Chief Executive Officer. “By leveraging our intellectual property to enter high-growth markets, and expanding our co-marketing initiatives, we are solidifying our position as a trusted partner to premier brands. Combined with our targeted operational efficiency initiatives, these efforts ensure Solésence remains lean, agile, and structured for long-term value creation.” **Second Quarter 2026 Financial Highlights** - Second-quarter revenue was $15.3 million, compared to $20.4 million in the second quarter of 2025. Results in the prior-year period benefited from a one-time revenue boost driven by a major Solésence product launch and initial inventory pipeline fill. - Gross profit in the second quarter was $4.7 million, compared to $6.4 million for the same period in 2025. - Gross margin in the second quarter was 31%, compared to 32% for the same period in 2025. - Net loss in the second quarter was $158,000, compared to net income of $3.2 million for the same period in 2025. **Accounting Update** As previously disclosed, the Company filed a Form NT 10-Q regarding its quarterly report for the period ended June 30, 2026. The Company has completed its evaluation regarding historical inventory costing allocation methodologies. The Company’s Quarterly Report on Form 10-Q for the second quarter ended June 30, 2026, has been filed with the U.S. Securities and Exchange Commission (SEC) and is accessible on the SEC’s website at www.sec.gov as well as in the Investor Relations section of the Company’s website at ir.solesence.com. **Second Quarter 2026 Conference Call Details** *Date/Time:* Wednesday, August 19, 2026 – 4:00 p.m. CT, 5:00 p.m. ET *Speakers*: Kevin Cureton, President & Chief Executive Officer and Laura Riffner, Chief Financial Officer *Webcast Link*: https://edge.media-server.com/mmc/p/ecgoveo8/ *Dial-In Link*: https://register-conf.media-server.com/register/BIb4a184933a544641a8f41396efd90a13 To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the option to have the system dial-out to you once the conference call begins. If you forget your PIN prior to the conference call, you can simply re-register. The call may also be accessed through the Company’s investor relations website, at https://ir.solesence.com/. Please join the conference call at least five minutes before the start time. **About Solésence, Inc.** Solésence, Inc. (Nasdaq: SLSN) is a leader in scientifically-driven health care solutions across beauty and life science categories. With a mission to deliver joy through innovation, inclusivity and the science of beautiful skin, we have redefined mineral-based sun protection by maximizing transparency, effectiveness, aesthetics, and wearability — empowering individuals to embrace beauty on their own terms. Combining best-in-class skin health solutions with the celebration of self-care, we allow brands to deliver unique product claims and attributes by seamlessly integrating protection, prevention, and treatment technologies into daily use products. Learn more at solesence.com. **Forward-Looking Statements** *This press release contains words such as “expects,” “shall,” “will,” “believes,” and similar expressions that are intended to identify forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements in this announcement are made based on the Company’s current beliefs, known events and circumstances at the time of publication, and as such, are subject in the future to unforeseen risks and uncertainties that could cause the Company’s results of operations, performance, and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, without limitation, the following: a decision by a customer to cancel a purchase order or supply agreement in light of the Company’s dependence on a limited number of key customers; uncertain demand for, and acceptance of, the Company’s engineered materials, ingredients, and fully formulated products; the Company’s manufacturing capacity and product mix flexibility in light of customer demand; the Company’s limited marketing experience; changes in development and distribution relationships; the impact of competitive products and technologies; the Company’s dependence on patents and protection of proprietary information; the resolution of litigation in which the Company may become involved; the impact of any potential new government regulations that could be difficult to respond to or too costly to comply with while remaining financially viable; the ability of the Company to maintain an appropriate electronic trading venue; and other factors described in the Company’s Form 10-K filed March 31, 2026. In addition, the Company’s forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties, or other contingencies.* **Media Contact:** media@solesence.com **Investor Relations Contact:** investors@solesence.com **SOLESENCE, INC** **CONSOLIDATED BALANCE SHEETS** **(Unaudited Consolidated Condensed)** **(in thousands except share and per share data)** **June 30,** **December 31,** **2026** **2025** **ASSETS** **(Unaudited)** **(Unaudited)** **Current assets:** Cash $ 1,046 $ 1,288 Trade accounts receivable 10,240 7,642 Allowance for credit losses (895 ) (806 ) Trade accounts receivable, net 9,345 6,836 Inventories, net 12,957 14,963 Prepaid expenses and other current assets 1,922 2,141 Total current assets 25,270 25,228 Equipment and leasehold improvements, net 14,794 14,329 Operating leases, right of use 6,337 6,913 Other assets, net 36 37 Total assets $ 46,437 $ 46,507 **LIABILITIES AND STOCKHOLDERS' EQUITY** **Current liabilities:** Line of credit, accounts receivable, related party 3,787 4,767 Current portion of line of credit, inventory, related party 9,500 - Current portion of debt, related parties 1,000 - Current portion of operating lease obligations 1,343 1,255 Accounts payable 4,968 4,098 Deferred revenue 1,937 930 Accrued expenses 3,478 2,879 Total current liabilities 26,013 13,929 Long-term portion of operating lease obligations 7,070 7,798 Long-term portion of line of credit, inventory, related party - 9,500 Long-term portion of debt, related parties - 1,000 Asset retirement obligations 200 194 Total long-term liabilities 7,270 18,492 **Stockholders' equity:** Preferred stock, $.01 par value, 24,088 shares authorized and no shares issued and outstanding - - Common stock, $.01 par value, 95,000,000 shares authorized; 70,632,445 and 70,614,045 shares issued and outstanding on March 31, 2026 and December 31, 2025, respectively 706 706 Additional paid-in capital 115,754 115,566 Accumulated deficit (103,306 ) (102,186 ) Total stockholders' equity 13,154 14,086 **Total liabilities and shareholders' equity** $ 46,437 $ 46,507 **SOLESENCE, INC** **CONSOLIDATED STATEMENTS OF OPERATIONS** **(Unaudited Consolidated Condensed)** **(in thousands except share and per share data)** **Three months ended** **Six months ended** **June 30,** **June 30,** **2026** **2025** **2026** **2025** **Revenue:** Product revenue $ 15,286 $ 20,261 $ 28,205 $ 34,836 Other revenue 46 98 85 148 Net revenue 15,332 20,359 28,290 34,984 Cost of revenue 10,584 13,916 20,400 24,895 Gross profit 4,748 6,443 7,890 10,089 **Operating expense:** Research and development expense 947 955 1,990 1,973 Selling, general and administrative expense 3,680 3,012 6,479 5,120 Net (loss) income from operations 121 2,476 (579 ) 2,996 Interest income Interest expense 279 87 543 263 Other nonoperating income - 1,234 2 1,234 Net (loss) income before provision for income taxes (158 ) 3,623 (1,120 ) 3,967 Provision for income taxes - 390 - 390 Net (loss) income $ (158 ) $ 3,233 $ (1,120 ) $ 3,577 Net (loss) income per share-basic $ - $ 0.04 $ (0.02 ) $ 0.05 Weighted average number of common shares outstanding - basic 70,637,199 70,200,039 70,631,380 70,151,928 Net (loss) income per share-diluted $ - $ 0.04 $ (0.02 ) $ 0.05 Weighted average number of common shares outstanding - diluted 70,637,199 72,580,679 70,631,380 72,497,929 **SOLESENCE, INC** **CONSOLIDATED STATEMENTS OF OPERATIONS - EXPANDED SCHEDULE** **(Unaudited Consolidated Condensed)** **(in thousands except share and per share data)** **Three months ended** **Six months ended** **June 30,** **June 30,** **2026** **2025** **2026** **2025** **Revenue:** Product revenue $ 15,286 $ 20,261 $ 28,205 $ 34,836 Other revenue 46 98 85 148 Net revenue 15,332 20,359 28,290 34,984 *Cost of revenue detail:* Depreciation 308 216 610 432 Non-Cash equity compensation 22 28 42 54 Other costs of revenue 10,254 13,672 19,748 24,409 Cost of revenue 10,584 13,916 20,400 24,895 Gross profit 4,748 6,443 7,890 10,089 **Operating expense:** *Research and development expense detail:* Depreciation 5 4 10 7 Non-Cash equity compensation 17 28 35 55 Other research and development expense 925 923 1,945 1,911 Research and development expense 947 955 1,990 1,973 *Selling, general and administrative expense detail:* Depreciation and amortization 10 6 16 11 Non-Cash equity compensation 40 64 86 138 Other selling, general and administrative expense 3,630 2,942 6,377 4,971 Selling, general and administrative expense 3,680 3,012 6,479 5,120 Net (loss) income from operations 121 2,476 (579 ) 2,996 Interest income Interest expense 279 87 543 263 Other nonoperating income - 1,234 2 1,234 Net (loss) income before provision for income taxes (158 ) 3,623 (1,120 ) 3,967 Provision for income taxes - 390 - 390 Net (loss) income $ (158 ) $ 3,233 $ (1,120 ) $ 3,577 Non-GAAP Disclosure (see note regarding Non-GAAP disclosures): Addback Interest, net 279 87 543 263 Addback Depreciation/Amortization 323 226 636 450 Addback Non-Cash Equity Compensation 79 120 163 247 Subtract Non-Cash Other Income - - - - Adjusted EBITDA $ 523 $ 3,666 $ 222 $ 4,537 ### Related Stocks - [SLSN.US](https://longbridge.com/en/quote/SLSN.US.md) ## Related News & Research - [Solesence delays quarterly 10-Q filing after discovering improper inventory costing method](https://longbridge.com/en/news/295972000.md) - [Solésence says prior financial statements no longer reliable after inventory accounting errors found](https://longbridge.com/en/news/296639029.md) - [SLSN: Revenue down in Q2 2026, but full-year growth and record second-half performance expected](https://longbridge.com/en/news/296407231.md) - [Algorhythm Holdings Reports Second Quarter 2026 Financial Results](https://longbridge.com/en/news/296124832.md) - [Solmate Infrastructure PLC (NASDAQ: SLMT) Continues SOL Accumulation with Additional Purchases as Holdings Surpass $100 Million | SLMT Stock News](https://longbridge.com/en/news/296486958.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**